BACKGROUND: Small cell lung cancer (SCLC) has the strongest association with smoking among lung cancers. The characteristics of never smokers with SCLC is not known. RESEARCH QUESTION: Are the clinical characteristics, prognostic factors, survival, genomic alterations, and tumor mutational burdens of SCLC in patients who have never smoked different from those who have smoked? STUDY DESIGN AND METHODS: A retrospective multicenter cohort study of patients with clinician-confirmed SCLC was performed with the use of a longitudinal and nationally representative electronic medical records database. Smoking history was assessed through technology-enabled abstraction and confirmed for never smokers via chart review. Genomic characteristics of never smoker patients with SCLC were examined with the use of a next-generation sequencing-based gene panel and whole exome sequencing. RESULTS: One hundred of 5,632 patients (1.8%) with SCLC were never smokers. Relative to smokers, never smokers were more likely to be female (66.0% vs 52.4%; P = .009) and present with extensive stage (70.0% vs 62.2%; P = .028). Never smokers had a higher proportion of patients in age groups 35 to 49 years (7.0% vs 3.0%; P = .006) and ≥80 years (17.0% vs 8.2%; P = .006). Known risk factors for lung cancer were found in <20% of never smokers. There were no overall survival differences between never smokers and smokers. Among patients with available genomic data (n = 9), never smoker SCLC were characterized by lower tumor mutational burden, a lower frequency of TP53 mutations, and an absence of mutational signatures related to tobacco exposure. INTERPRETATION: The sex- and age-specific distribution of SCLC among never smokers, along with differences that were identified by genomic analyses, suggests a distinct biology of SCLC in never smokers compared with smokers. Published by Elsevier Inc.
BACKGROUND:Small cell lung cancer (SCLC) has the strongest association with smoking among lung cancers. The characteristics of never smokers with SCLC is not known. RESEARCH QUESTION: Are the clinical characteristics, prognostic factors, survival, genomic alterations, and tumor mutational burdens of SCLC in patients who have never smoked different from those who have smoked? STUDY DESIGN AND METHODS: A retrospective multicenter cohort study of patients with clinician-confirmed SCLC was performed with the use of a longitudinal and nationally representative electronic medical records database. Smoking history was assessed through technology-enabled abstraction and confirmed for never smokers via chart review. Genomic characteristics of never smoker patients with SCLC were examined with the use of a next-generation sequencing-based gene panel and whole exome sequencing. RESULTS: One hundred of 5,632 patients (1.8%) with SCLC were never smokers. Relative to smokers, never smokers were more likely to be female (66.0% vs 52.4%; P = .009) and present with extensive stage (70.0% vs 62.2%; P = .028). Never smokers had a higher proportion of patients in age groups 35 to 49 years (7.0% vs 3.0%; P = .006) and ≥80 years (17.0% vs 8.2%; P = .006). Known risk factors for lung cancer were found in <20% of never smokers. There were no overall survival differences between never smokers and smokers. Among patients with available genomic data (n = 9), never smoker SCLC were characterized by lower tumor mutational burden, a lower frequency of TP53 mutations, and an absence of mutational signatures related to tobacco exposure. INTERPRETATION: The sex- and age-specific distribution of SCLC among never smokers, along with differences that were identified by genomic analyses, suggests a distinct biology of SCLC in never smokers compared with smokers. Published by Elsevier Inc.
Entities:
Keywords:
COSMIC signature 4; never smoker; small cell lung cancer; tumor mutation burden
Authors: Ana Tavares e Castro; Joana Clemente; L Carvalho; Sara Freitas; Jessica Cemlyn-Jones Journal: Lung Cancer Date: 2016-01-12 Impact factor: 5.705
Authors: Wendy Chang; Andrew S Brohl; Rajesh Patidar; Sivasish Sindiri; Jack F Shern; Jun S Wei; Young K Song; Marielle E Yohe; Berkley Gryder; Shile Zhang; Kathleen A Calzone; Nityashree Shivaprasad; Xinyu Wen; Thomas C Badgett; Markku Miettinen; Kip R Hartman; James C League-Pascual; Toby N Trahair; Brigitte C Widemann; Melinda S Merchant; Rosandra N Kaplan; Jimmy C Lin; Javed Khan Journal: Clin Cancer Res Date: 2016-03-18 Impact factor: 12.531
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Ludmil B Alexandrov; Young Seok Ju; Kerstin Haase; Peter Van Loo; Iñigo Martincorena; Serena Nik-Zainal; Yasushi Totoki; Akihiro Fujimoto; Hidewaki Nakagawa; Tatsuhiro Shibata; Peter J Campbell; Paolo Vineis; David H Phillips; Michael R Stratton Journal: Science Date: 2016-11-04 Impact factor: 47.728
Authors: Nicholas Kwiatkowski; Tinghu Zhang; Peter B Rahl; Brian J Abraham; Jessica Reddy; Scott B Ficarro; Anahita Dastur; Arnaud Amzallag; Sridhar Ramaswamy; Bethany Tesar; Catherine E Jenkins; Nancy M Hannett; Douglas McMillin; Takaomi Sanda; Taebo Sim; Nam Doo Kim; Thomas Look; Constantine S Mitsiades; Andrew P Weng; Jennifer R Brown; Cyril H Benes; Jarrod A Marto; Richard A Young; Nathanael S Gray Journal: Nature Date: 2014-06-22 Impact factor: 49.962
Authors: Jill E Kucab; Xueqing Zou; Sandro Morganella; Madeleine Joel; A Scott Nanda; Eszter Nagy; Celine Gomez; Andrea Degasperi; Rebecca Harris; Stephen P Jackson; Volker M Arlt; David H Phillips; Serena Nik-Zainal Journal: Cell Date: 2019-04-11 Impact factor: 41.582
Authors: Yufei Wang; James D McKay; Thorunn Rafnar; Zhaoming Wang; Maria N Timofeeva; Peter Broderick; Xuchen Zong; Marina Laplana; Yongyue Wei; Younghun Han; Amy Lloyd; Manon Delahaye-Sourdeix; Daniel Chubb; Valerie Gaborieau; William Wheeler; Nilanjan Chatterjee; Gudmar Thorleifsson; Patrick Sulem; Geoffrey Liu; Rudolf Kaaks; Marc Henrion; Ben Kinnersley; Maxime Vallée; Florence LeCalvez-Kelm; Victoria L Stevens; Susan M Gapstur; Wei V Chen; David Zaridze; Neonilia Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Dana Mates; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Hans E Krokan; Maiken Elvestad Gabrielsen; Frank Skorpen; Lars Vatten; Inger Njølstad; Chu Chen; Gary Goodman; Simone Benhamou; Tonu Vooder; Kristjan Välk; Mari Nelis; Andres Metspalu; Marcin Lener; Jan Lubiński; Mattias Johansson; Paolo Vineis; Antonio Agudo; Francoise Clavel-Chapelon; H Bas Bueno-de-Mesquita; Dimitrios Trichopoulos; Kay-Tee Khaw; Mikael Johansson; Elisabete Weiderpass; Anne Tjønneland; Elio Riboli; Mark Lathrop; Ghislaine Scelo; Demetrius Albanes; Neil E Caporaso; Yuanqing Ye; Jian Gu; Xifeng Wu; Margaret R Spitz; Hendrik Dienemann; Albert Rosenberger; Li Su; Athena Matakidou; Timothy Eisen; Kari Stefansson; Angela Risch; Stephen J Chanock; David C Christiani; Rayjean J Hung; Paul Brennan; Maria Teresa Landi; Richard S Houlston; Christopher I Amos Journal: Nat Genet Date: 2014-06-01 Impact factor: 38.330